This license is a continuation of the strategic partnership agreement signed by both parties in Nov. 2020. As a cutting-edge high-tech biotechnology enterprise dedicated to the R&D and services of innovative biopharmaceuticals, Sanyou has established a world-leading core technology platform for integrated R&D and preclinical development of innovative biological drugs, along with a world-class "super-trillion innovative biologics discovery platform". Huadong Medicine, on the other hand, is an innovative international pharmaceutical company driven by scientific R&D and technological innovation, which possesses years of technical expertise, clinical insights, and integrated commercial capabilities in the therapeutic area of oncology. The collaboration between the two parties is based on the complementary strengths of both parties. By leveraging their respective advantages, both parties will work hand in hand to make contributions to the advancement of innovative biopharmaceuticals.

Dr. Jeffery Liu, Chief Scientific Officer of Huadong Medicine, stated, "Since embarking on our innovative transformation, Huadong Medicine has been consistently increasing its R&D investments in the therapeutic area of oncology. We have been enriching our pipeline layout of innovative drug R&D through a combination of independent R&D, collaborative and commissioned development, and pipeline license-in. We are delighted to further collaborate with Sanyou, as this agreement marks an important milestone in deepening our partnership. We hope that this project can progress into clinical stages in the near future, benefiting patients in need."

"We are greatly honored to establish a further strategic partnership with Huadong Medicine," stated Dr. Guojun Lang, CEO of Sanyou. "As an international pharmaceutical company, Huadong Medicine has been committed to strengthening its innovation and influence in the therapeutic area of oncology and has solid strength in transforming innovative projects into commercialized leading drugs. The signing of this agreement signifies the milestone achievement in the development of this innovative drug candidate. In the future, Sanyou will continue to exert our utmost efforts to support our partners in accelerating the innovative drug R&D process."